New York-based venture firm Dimension Capital has raised an $800 million third fund, marking a 60% increase over its previous vehicle.
Key facts
- •Dimension Capital was founded in late 2022 by Zavian Dar, Adam Goulburn, and Nan Li.
- •The new $800 million fund is 60% larger than the firm's second fund.
- •Chai Discovery, a portfolio company, raised $400 million at a $3.8 billion valuation.
- •New Limit, another portfolio company, completed a Series C round at a $3.1 billion valuation.
- •Dimension Capital gained shares in Anthropic following the acquisition of Coefficient Bio.
Dimension Capital, a New York-based venture firm focused on the intersection of science and compute, announced an $800 million fund on Tuesday. The firm, founded in late 2022, has grown rapidly, with this new fund representing a 60% increase over the $500 million vehicle it announced 18 months ago.
By the numbers
Investment Strategy and Portfolio
The firm was launched by partners Zavian Dar, Adam Goulburn, and Nan Li with a focus on deep-tech companies that bridge the gap between biotechnology and software. The partners noted that the speed at which their investment thesis has materialized has exceeded their initial expectations.
Recent Portfolio Activity
Dimension Capital’s recent investments include a co-led $30 million seed round in Chai Discovery, an AI drug development startup that recently reached a $3.8 billion valuation. The firm also invested in the anti-aging startup New Limit, which was co-founded by Coinbase CEO Brian Armstrong and reached a $3.1 billion valuation following a Series C round earlier this month. Additionally, the firm holds shares in AI company Anthropic, acquired after Anthropic purchased Dimension’s portfolio company Coefficient Bio for a reported $400 million this spring.
Timeline
- Late 2022Dimension Capital was founded.
- 2024Dimension Capital co-led a $30 million seed investment in Chai Discovery.
- January 2025Dimension Capital backed New Limit during its Series A round.
- Spring 2025Anthropic acquired Coefficient Bio for a reported $400 million.
- Earlier this monthNew Limit completed a Series C round at a $3.1 billion valuation.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by TechCrunch.
